Children's oral product

ArtaBiotic Baby Drops

Children's probiotic and lactase oral drops

Children's oral drops containing six probiotic strains, 1 billion CFU, and 1,500 IU lactase per ml.

Product details

Composition and product guidance

Named strains: Bifidobacterium animalis subsp. lactis BS01 (LMG P-21384)
Bifidobacterium longum subsp. infantis BI02 (DSM 24687)
Lactobacillus acidophilus LA02 (DSM 21717)
Lactobacillus reuteri LRE02 (DSM 23878)
Lacticaseibacillus rhamnosus GG (ATCC 53103)
Lactobacillus salivarius LS01 (DSM 22775)
Probiotic amount: 1 billion CFU per ml
Lactase: 1,500 international units per ml
Other ingredients: MCT oil, sunflower oil and silicon dioxide

Listed age range: From birth
General directions: 1 ml daily with food or a meal, or as directed by a physician
Administration: Shake the bottle thoroughly before use.
Do not add the drops to hot food or drinks.

Oral antibiotics: A minimum two-hour interval is recommended.
Other medicines: Consult a physician or pharmacist before use.
Adverse-effect statement: No adverse effects were reported when used at the recommended amount.
After opening: Use within one month.
Manufacturer / licence holder: Behyan Teb Arta

Li YT et al. Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhea: A systematic review with meta-analysis — World Journal of Gastroenterology, 2019.
Del Piano M et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study — Journal of Clinical Gastroenterology, 2010 (BS01; adults).
Niccoli AA et al. Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis — Journal of Clinical Gastroenterology, 2014.
Margiotta G et al. Effect of Lactobacillus reuteri LRE02-Lactobacillus rhamnosus LR04 combination and gastrointestinal functional disorders in an Emergency Department pediatric population — European Review for Medical and Pharmacological Sciences, 2021.
Drago L et al. Effect of Limosilactobacillus reuteri LRE02-Lacticaseibacillus rhamnosus LR04 Combination on Antibiotic-Associated Diarrhea in a Pediatric Population: A National Survey — Journal of Clinical Medicine, 2020.